Renal Tissue Damage Induced by Acute Kidney Injury in Sepsis Rat Model Is Inhibited by Cynaropicrin via IL-1β and TNF-α Down-Regulation

Acute kidney injury (AKI), one of the frequently diagnosed and serious sepsis induced complication has high morbidity and mortality. The present study investigated the effect of cynaropicrin on AKI induced pathological damage in rat model in vivo . Treatment with cynaropicrin suppressed AKI induced...

Full description

Saved in:
Bibliographic Details
Published in:Doklady. Biochemistry and biophysics 2021-03, Vol.497 (1), p.151-157
Main Authors: Cai, Danlei, Duan, Hongdan, Fu, Yangshan, Cheng, Zhongfeng
Format: Article
Language:English
Subjects:
Bcl-2 protein
Biochemistry
Biological and Medical Physics
Biomedical and Life Sciences
Biophysics
Creatinine
IL-1β
Inflammation
Kidneys
Life Sciences
Molecular Biology
Morbidity
Rodents
Sepsis
Survival
Tumor necrosis factor-α
Urea
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute kidney injury (AKI), one of the frequently diagnosed and serious sepsis induced complication has high morbidity and mortality. The present study investigated the effect of cynaropicrin on AKI induced pathological damage in rat model in vivo . Treatment with cynaropicrin suppressed AKI induced urea nitrogen and creatinine in the rat serum in dose-dependent manner. Development of sepsis mediated renal injury in rats was also effectively prevented on treatment with cynaropicrin. Secretion of AKI-induced IL-1β and TNF-α in renal tissues was alleviated significantly in rats by cynaropicrin treatment. Additionally, in cynaropicrin-treated rats renal tissues AKI induced Bax expression was alleviated while as Bcl-2 was promoted compared to AKI rats. Cynaropicrin treatment improved the survival rate of the rats with AKI. Cynaropicrin inhibits renal tissue damage and increase survival rate in AKI rat model. The mechanism involves alleviation of inflammatory cytokine secretion and promotion of Bcl‑2 expression. Thus, cynaropicrin may be used as therapeutic agent for treatment of AKI.
ISSN:1607-6729
1608-3091
DOI:10.1134/S1607672921020022